New drug development
The upside to the alarming increase in antibiotic resistance is that it has fueled some of the new drug development in dermatology. According to Dr. Eichenfield, there are new topical retinoids and other agents such as nitric oxide-based medications currently in clinical trials that are not targeted toward bacteria or do not induce bacterial resistance. Other novel topical agents in the pipeline are designed to target acetyl coenzyme-A carboxylase and act to inhibit sebum production, which may prove to be very useful in ameliorating acne severity.
“As we await these new medications in the pipeline, it is important that, for each patient treatment decision, we realize that we are influencing the individual and collective microbiome, as well as the community microbiological ecology. So, as we write our scripts, it is paramount that we balance the best therapy for each patient with the impact that those therapies may have,” Dr. Eichenfield says.
Disclosure: Dr. Eichenfield reports no relevant disclosures.